Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  EXACT Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/15/2019 05/16/2019 05/17/2019 05/20/2019 05/21/2019 Date
95.37(c) 97.74(c) 96.19(c) 96.04(c) 96.74 Last
1 330 541 1 495 785 1 336 721 1 355 578 810 561 Volume
+3.66% +2.49% -1.59% -0.16% +0.73% Change
More quotes
Financials (USD)
Sales 2019 747 M
EBIT 2019 -239 M
Net income 2019 -284 M
Finance 2019 204 M
Yield 2019 -
Sales 2020 1 070 M
EBIT 2020 -119 M
Net income 2020 -151 M
Finance 2020 153 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 16,3x
EV / Sales2020 11,4x
Capitalization 12 402 M
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based... 
Sector
Biotechnology & Medical Research
Calendar
05/21 | 02:00pmPresentation
More about the company
Surperformance© ratings of EXACT Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on EXACT SCIENCES CORPORATION
05/20EXACT SCIENCES : Advances Pipeline Capabilities with Mayo Clinic
PU
05/17EXACT SCIENCES : Presents New Data Reinforcing Performance of Cologuard®
PU
05/03EXACT SCIENCES : starts to see payoff from Pfizer marketing tie-up
AQ
05/01EXACT SCIENCES : to participate in May investor conferences
PU
04/30EXACT SCIENCES : 1Q Earnings Snapshot
AQ
04/30EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
04/30EXACT SCIENCES : First-quarter revenue and Cologuard test volume increased 79 pe..
PU
04/24EXACT SCIENCES : Older workers helped fuel recent U.S. growth. Can it last?
RE
04/08EXACT SCIENCES : schedules first-quarter 2019 earnings call
PU
03/27EXACT SCIENCES : JEFFREY THOMAS ELLIOTT, CFA Joins Exagens Board of Directors
AQ
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
12:51aGlobal chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart EXACT SCIENCES CORPORATION
Duration : Period :
EXACT Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 114 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey T. Elliott Chief Financial Officer
Barry M. Berger Co-Chief Medical Officer & Head-Medical Affairs
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION52.20%12 402
IQVIA HOLDINGS INC15.06%26 365
LONZA GROUP24.54%23 366
CELLTRION, INC.--.--%21 024
INCYTE CORPORATION20.82%16 555
SEATTLE GENETICS, INC.13.63%10 715